Research programme: immunomodulatory drugs - Celgene

Drug Profile

Research programme: immunomodulatory drugs - Celgene

Alternative Names: CC-0478765; CC-0478995; CC-13097; CC-15965

Latest Information Update: 16 Jan 2009

Price : $50

At a glance

  • Originator Celgene Corporation
  • Class Phthalimides; Piperidones; Small molecules
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Inflammation

Most Recent Events

  • 07 May 2007 This programme is still in active development in the USA
  • 20 Oct 2004 Preclinical trials in Inflammation in USA (PO)
  • 20 Oct 2004 Preclinical trials in Cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top